Study finds elevated risk of certain rare blood cancers after chemotherapy for most solid tumors
, by DCEG Staff
Findings from a new study by researchers at the National Cancer Institute (NCI) show that patients treated with chemotherapy for most solid tumors during 2000–2014 experienced an increased risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML). The study, which used U.S. population-based cancer registry data from NCI’s Surveillance, Epidemiology, and End Results (SEER) program and treatment information from the SEER–Medicare database, was published December 20, 2018, in JAMA Oncology.
Advances in treatment over the last several decades have resulted in improved survival for patients with many types of cancer. However, survivors may be at increased risk of developing a subsequent treatment-related cancer. In this study, researchers aimed to quantify the risk of developing tMDS/AML, a rare but often fatal blood cancer, in patients treated with chemotherapy.
Read the full NIH Press Release.
Reference:
Morton L et al. "Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era." JAMA Oncology December 20, 2018. [Epub ahead of print] DOI: 10.1001/jamaoncol.2018.5625